EE200100693A - Uus ravimvorm - Google Patents

Uus ravimvorm

Info

Publication number
EE200100693A
EE200100693A EEP200100693A EEP200100693A EE200100693A EE 200100693 A EE200100693 A EE 200100693A EE P200100693 A EEP200100693 A EE P200100693A EE P200100693 A EEP200100693 A EE P200100693A EE 200100693 A EE200100693 A EE 200100693A
Authority
EE
Estonia
Prior art keywords
dosage form
omeprazole
core material
new dosage
alkaline
Prior art date
Application number
EEP200100693A
Other languages
English (en)
Estonian (et)
Inventor
Johan Lundberg Per
Sj�blom Brita
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200100693A publication Critical patent/EE200100693A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
EEP200100693A 1999-06-22 2000-06-20 Uus ravimvorm EE200100693A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902386A SE9902386D0 (sv) 1999-06-22 1999-06-22 New formulation
PCT/SE2000/001310 WO2000078293A1 (en) 1999-06-22 2000-06-20 New formulation

Publications (1)

Publication Number Publication Date
EE200100693A true EE200100693A (et) 2003-02-17

Family

ID=20416209

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100693A EE200100693A (et) 1999-06-22 2000-06-20 Uus ravimvorm

Country Status (29)

Country Link
EP (1) EP1191926B1 (uk)
JP (1) JP2003502359A (uk)
KR (1) KR100717661B1 (uk)
CN (1) CN1243547C (uk)
AT (1) ATE291901T1 (uk)
AU (1) AU778158B2 (uk)
BR (1) BR0011894A (uk)
CA (1) CA2376226C (uk)
CZ (1) CZ20014579A3 (uk)
DE (1) DE60019116T2 (uk)
DK (1) DK1191926T3 (uk)
EE (1) EE200100693A (uk)
ES (1) ES2235912T3 (uk)
HK (1) HK1044480B (uk)
HU (1) HUP0201489A3 (uk)
IL (2) IL146818A0 (uk)
IS (1) IS6209A (uk)
MX (1) MXPA01012636A (uk)
NO (1) NO20016346L (uk)
NZ (1) NZ516186A (uk)
PL (1) PL352873A1 (uk)
PT (1) PT1191926E (uk)
RU (1) RU2240110C2 (uk)
SE (1) SE9902386D0 (uk)
SK (1) SK285326B6 (uk)
TR (1) TR200103693T2 (uk)
UA (1) UA73302C2 (uk)
WO (1) WO2000078293A1 (uk)
ZA (1) ZA200109803B (uk)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
EP1605919A1 (en) * 2003-02-28 2005-12-21 Ranbaxy Laboratories, Ltd. Stable pharmaceutical composition of rabeprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005027876A1 (en) * 2003-08-28 2005-03-31 Ranbaxy Laboratories Limited Pharmaceutical compositions of benzimidazole and processes for their preparation
WO2005020954A2 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2005275594A1 (en) * 2004-08-23 2006-03-02 Synergy Pharmaceuticals Pte Ltd Gastric therapies and compositions therefor
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
ZA200805646B (en) * 2005-12-28 2009-12-30 Takeda Pharmaceutical Controlled release solid preparation
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
WO2008044236A2 (en) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
WO2010151216A1 (en) 2009-06-25 2010-12-29 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
JP6121990B2 (ja) 2011-05-13 2017-04-26 イービー アイピー ハイブリタブス ビー．ブイ． 薬物送達システム
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
EP3089666B1 (en) 2013-12-31 2020-08-19 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
RU2614730C1 (ru) * 2016-02-05 2017-03-28 Игорь Юрьевич Чичерин Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
WO2017145146A1 (en) * 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
JP6462625B2 (ja) * 2016-04-06 2019-01-30 ニプロ株式会社 カルシウムブロッカーを含有する錠剤
JP6426115B2 (ja) * 2016-04-06 2018-11-21 ニプロ株式会社 カルシウムブロッカーを含有する固形医薬組成物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
EP0941074B1 (en) * 1996-11-06 2004-07-21 Wockhardt Europe Limited Delayed delivery system for acid-sensitive drugs
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
JP4546643B2 (ja) * 1997-12-08 2010-09-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸不安定な活性化合物を含有する新規の坐剤形
ATE321538T1 (de) * 1998-08-12 2006-04-15 Altana Pharma Ag Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole

Also Published As

Publication number Publication date
PL352873A1 (en) 2003-09-08
IL146818A0 (en) 2002-07-25
CA2376226C (en) 2009-10-20
SK18252001A3 (sk) 2002-09-10
HK1044480A1 (en) 2002-10-25
KR20020012002A (ko) 2002-02-09
ZA200109803B (en) 2003-02-28
PT1191926E (pt) 2005-07-29
JP2003502359A (ja) 2003-01-21
NO20016346D0 (no) 2001-12-21
HK1044480B (zh) 2005-08-26
KR100717661B1 (ko) 2007-05-14
DE60019116D1 (de) 2005-05-04
ATE291901T1 (de) 2005-04-15
CN1356893A (zh) 2002-07-03
RU2240110C2 (ru) 2004-11-20
HUP0201489A2 (hu) 2002-11-28
ES2235912T3 (es) 2005-07-16
AU6034400A (en) 2001-01-09
DK1191926T3 (da) 2005-06-13
NZ516186A (en) 2003-11-28
SE9902386D0 (sv) 1999-06-22
SK285326B6 (sk) 2006-11-03
MXPA01012636A (es) 2002-06-21
CN1243547C (zh) 2006-03-01
CA2376226A1 (en) 2000-12-28
AU778158B2 (en) 2004-11-18
EP1191926B1 (en) 2005-03-30
EP1191926A1 (en) 2002-04-03
WO2000078293A1 (en) 2000-12-28
NO20016346L (no) 2002-02-18
IL146818A (en) 2007-10-31
DE60019116T2 (de) 2006-02-09
TR200103693T2 (tr) 2002-05-21
UA73302C2 (en) 2005-07-15
BR0011894A (pt) 2002-04-02
CZ20014579A3 (cs) 2002-05-15
IS6209A (is) 2001-12-21
HUP0201489A3 (en) 2004-05-28

Similar Documents

Publication Publication Date Title
EE200100693A (et) Uus ravimvorm
NO20012222L (no) Farmasöytisk formulering innbefattende omeprazol
EE05383B1 (et) Polarlkarboksamiidhendid,ÁnendeÁvalmistamineÁjaÁkasutamineÁlipiiditasetÁalandavateÁtoimeainetenaÁningÁneidÁsisaldavÁfarmatseutilineÁkompositsioon
EE200000329A (et) Oraalne manustamisvorm happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod ja happes ebapüsivat toimeainet sisaldava toimeaineühiku kasutamine
MY129356A (en) Electrospun pharmaceutical compositions
SE9702000D0 (sv) New pharmaceutical formulation
DK1169024T3 (da) Prægelatineret stivelse i en formulering med kontrolleret frigivelse
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
DK0591424T3 (da) Diltiazem-holdigt lægemiddel med forlænget frigivelse
TR200001942T2 (tr) Opioid agonist/antagonist kombinasyonlar
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
GB9025372D0 (en) Pharmaceutical dosage forms
ATE333896T1 (de) Vaskularisierungsinhibitoren
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
ATE254851T1 (de) Iod-herstellungszusammensetzung
SE9604752D0 (sv) Formulation and use
MX9203221A (es) Compuesto farmacologicamente activo, preparacion y empleo.
MY127600A (en) Solid oral dosage forms of valsartan